Market Pulse63Bullish

Globus Medical, Inc.Opportunity Rank #128(GMED) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$78.11

Last updated: Jul 13, 2026

Price vs Intrinsic Value

$78.11
Price
$154.81
Intrinsic Value
Undervalued by 98%MOS: $123.85

Fundamental Score

74/100
Bullish

Weighted across 6 signals

Narrative Score

53/100
Weak

No change vs previous

Trend Score

26/100
Weak

As of 2026-07-10

The intrinsic value of Globus Medical, Inc. (GMED) is estimated at $154.81 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $78.11, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 7.93% long-term growth rate and a 9.00% discount rate (calculated: 8.77%), reflecting expected future free cash flow and cost of capital.

The intrinsic value of Globus Medical, Inc. (GMED) is estimated at $154.81 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $78.11, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 7.93% long-term growth rate and a 9.00% discount rate (calculated: 8.77%), reflecting expected future free cash flow and cost of capital.

Valuation Details

$154.81
98.19% upside
20% margin of safety: $123.85
Years: 10Growth Rate: 7.93%
Want to create your own valuation? Create a free account.

Capital Efficiency

Average Quarterly ROIC
3.15%
Cost of Capital (estimated)7%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.

Fundamental Details

74/100
BullishWeighted across 6 signals
DCF Discount
98.2% discount to price
100
FCF Yield
9.1% trailing FCF yield
100
ROIC vs WACC
ROIC 3.2% vs WACC 7.0% (0.5x)
23
Net Debt / FCF
Net cash position
100
Buybacks
Share count growing
30
FCF CAGR (5Y)
29.5% 5Y FCF CAGR
100
Strengths: DCF Discount, FCF Yield. Concerns: ROIC vs WACC, Buybacks.

Narrative Details

53/100
Weak
Vs 6-Month Baseline:Low (20th pct)Weighted across 6 recent drivers
Trend: StableConfidence: 79%Updated: 2d ago
Sources: 32 (27 News · 5 Analyst)
Drivers(last 30 days)
21 news sentiment+0.3
3 regulatory scrutiny+0.0
Upgrade headlines+0.0
Margin pressure+0.0
Legal risk-0.0
5 analyst reiterations0.0

Trend Details

26/100
WeakAs of 2026-07-10309 daily bars used
3M Relative Strength vs SPY-25.6%
6M Relative Strength vs SPY-23.2%
Price vs 50 EMA-4.3%
Price vs 21 EMA38 · -1.9%
Price vs 50 EMA29 · -4.3%
21 EMA vs 50 EMA30 · -2.5%
3M RS vs SPY1 · -25.6%
6M RS vs SPY7 · -23.2%
Distance from 52W High61 · -19.3%

Investment Coach

Updating... 31d ago
BUYConfidence: 65%
Thesis
Globus Medical, Inc. is undervalued with an estimated fair value nearly 95% above its current price, supported by a strong fundamental score and a healthy free cash flow yield of 8.7%. Despite trailing its cost of capital, the company shows improving narrative trends and robust free cash flow growth.
Key Risk
The key risk is the negative spread between ROIC and WACC, indicating returns currently do not cover the cost of capital.
Signals To Watch
  • Monitor whether valuation discount remains above 10%.
  • Track ROIC vs WACC spread for sustained improvement.
  • Follow narrative trend for meaningful shifts in the score direction.
Ask the Coach - Available with
Historical Growth Rates
Free Cash Flow- - -Trend CAGR: 7.93%5 Year CAGR: 23.49%

Free Cash Flow (in millions)

TTM20252024202320222021202020192018201720162015201420132012201120102009
$957$918$636$322$253$333$262$243$241$211$213$173$104$117$101$99$84$58

How Intrinziq Estimates Fair Value

Intrinziq estimates Globus Medical, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Globus Medical, Inc.Healthcare

Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.